We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




First-Ever POC Analyzer Reads Patient's Immune System to Detect Diseases Before Symptoms Present

By LabMedica International staff writers
Posted on 19 May 2023
Print article
Image: The Immune Reveal point-of-care system goes beyond routine lab tests (Photo courtesy of Immune IQ)
Image: The Immune Reveal point-of-care system goes beyond routine lab tests (Photo courtesy of Immune IQ)

Each year, sepsis affects over 50 million individuals worldwide and accounts for nearly 20% of all fatalities. Additionally, sepsis poses a substantial economic strain, with projected costs exceeding USD 62 billion annually in the U.S. alone. However, rapid diagnosis and treatment could potentially prevent up to 80% of sepsis-related deaths. Now, a breakthrough point-of-care diagnostic platform that leverages the power of the human immune system is poised to address the two main challenges associated with sepsis: broad screening and rapid identification.

Immune Reveal, a first-of-its-kind point-of-care diagnostic platform, is a collaborative creation of Immune IQ (Twin Cities, MN, USA) and Honeywell (Charlotte, NC, USA). This groundbreaking platform integrates automatic disease screening with confirmatory tests to rapidly offer unique insights into various diseases, such as sepsis, heart disease, cancer, and COVID-19. The Immune Reveal platform offers diagnostic information quicker and more cost-effectively than ever before. With one of the most powerful data sets in the industry and the incorporation of artificial intelligence within its system, Immune Reveal could redefine the standard of care in diagnosis and treatment.

Immune Reveal generates one of the industry's most powerful data sets, which, when translated by artificial intelligence, can " read " diseases that a patient's immune system has detected even before the appearance of symptoms. This game-changing approach paves the way for a new era of integrated tests that can perform disease screening, confirmation testing, and precision treatment testing in minutes using the same card and sample. Immune IQ plans to commercialize sepsis detection as the initial test on the Immune Reveal platform. A recent clinical study successfully showcased Immune Reveal's ability to consistently generate a large cellular dataset. The combination of this data has been independently demonstrated in peer-reviewed publications to yield highly accurate sepsis detection.

"The human immune system is widely recognized as a near-perfect tool for detecting disease, even far in advance of noticeable symptoms. Immune Reveal is the first platform that can both read and decode the immune system's data in as soon as five minutes," said Immune IQ founder and CEO, David Deetz.

Related Links:
Immune IQ
Honeywell

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.